JP Morgan Reiterates Sell Rating on QuidelOrtho
JP Morgan maintains its sell rating on QuidelOrtho, setting a $12 price target, a 31.51% downside from the current price.
Key Points
- JP Morgan reiterated its sell rating on QuidelOrtho Corporation (QDEL) with a $12 price target on July 1, 2026.
- JP Morgan's $12 price target implies 31.51% downside from QuidelOrtho Corporation's ($QDEL) current $17.52 share price.
- Shares of QDEL traded at $17.52 on Wednesday, with the company having a market cap of about $1.19 billion.
- Analysts from JP Morgan, Jefferies, Citigroup, and UBS have various ratings, with JP Morgan's being the most bearish.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
JP Morgan has reiterated its sell rating on QuidelOrtho Corporation (NasdaqGS: QDEL), setting a price target of $12. This decision was announced on July 1, 2026, by analyst Casey Woodring. The stock traded at $17.52 on Wednesday.
JP Morgan vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
QuidelOrtho Corporation Stock Up 18.9%
Shares of QuidelOrtho traded near $17.52 on Wednesday. The company has a market cap of about $1.19 billion and a forward P/E ratio of 7.18. Its beta is 0.759, indicating lower volatility compared to the market. The stock has seen a 52-week low of $9.92 and a high of $35.58, with a 50-day moving average of $12.60 and a 200-day moving average of $22.17. The company's debt-to-equity ratio is quite high at 155.27.
$QDEL price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
QuidelOrtho reported revenue of approximately $2.66 billion, although it experienced a revenue decline of 10.5%. The company is not currently profitable, with a net margin of -45.57% and a return on equity of -49.95%. The next earnings report is scheduled for July 29, 2026.
Insider Buying and Selling at QuidelOrtho Corporation
Several insiders made recent purchases on June 25, 2026. John Chiminski acquired 1,109 shares, while Edward Michael bought 1,053 shares. Mary Lake Ph Polan purchased 15,532 shares, and Kenneth Widder acquired a total of 17,529 shares across two transactions. Kenneth Buechler also bought 3,661 shares. These transactions were not part of any pre-planned trading program.
Analysts Set New Price Targets
On July 1, 2026, JP Morgan maintained its sell rating on QuidelOrtho with a $12 price target. Previously, on May 7, 2026, Jefferies downgraded the stock to a hold rating with a $12.50 target. Citigroup and UBS have maintained hold ratings with targets of $13 and $17, respectively. The consensus among analysts is a hold rating, with an average price target of $18.63 based on four analyst opinions.
About QuidelOrtho Corporation
QuidelOrtho Corporation, headquartered in San Diego, CA, provides diagnostic testing solutions. Operating in the healthcare sector, the company focuses on medical devices. It has four main business units: Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics. QuidelOrtho's products are used globally across various healthcare settings. The company was founded in 1979 and employs about 6,500 people.
Bottom Line
JP Morgan's reiterated sell rating on QuidelOrtho with a $12 target reflects a bearish outlook. Investors often watch these ratings closely, though it's important to remember that analyst opinions are just one piece of the puzzle. QuidelOrtho's financials reveal challenges with profitability, and upcoming earnings will be critical to watch. As always, 13F filings and analyst reports are backward-looking, providing a snapshot of past activities and opinions.
Get QuidelOrtho Corporation alerts
New 13F filings, insider trades, and analyst moves on $QDEL, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.